| P2093 | author name string | Keith A Crutcher | |
| | Marcos A Marques | |
| | Phillip A Owens | |
| P2860 | cites work | Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease | Q22248076 |
| | Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation | Q24291128 |
| | Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study | Q24319783 |
| | Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E | Q28292492 |
| | Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease | Q48594192 |
| | Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease | Q48795523 |
| | A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity | Q48864142 |
| | Apolipoprotein E is synthesized in the retina by Müller glial cells, secreted into the vitreous, and rapidly transported into the optic nerve by retinal ganglion cells | Q49061077 |
| | Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease | Q49171338 |
| | Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. | Q50699084 |
| | Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. | Q52271466 |
| | Economics, pharmacoeconomics and drug discovery for dementias. | Q53252734 |
| | Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. | Q53316390 |
| | Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? | Q54069183 |
| | Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. | Q54638192 |
| | Apolipoprotein-E degradation in human very low density lipoproteins by plasma protease(s): chemical and biological consequences | Q67283271 |
| | Apolipoprotein E: receptor binding properties | Q68941964 |
| | Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3 | Q68952730 |
| | The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments | Q70169929 |
| | Cellular and molecular biology of lipoprotein metabolism: characterization of lipoprotein receptor-ligand interactions | Q70178535 |
| | Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid | Q70687889 |
| | Expression of apolipoprotein E mRNA in rat microglia | Q71538993 |
| | Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM | Q72015355 |
| | Localization of a Domain in Apolipoprotein E with both Cytostatic and Cytotoxic Activity | Q72046593 |
| | Neurite degeneration elicited by apolipoprotein E peptides | Q72408843 |
| | Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated | Q73507862 |
| | Apolipoprotein E: cholesterol transport protein with expanding role in cell biology | Q28294791 |
| | Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth | Q28771743 |
| | The endosomal trafficking of apolipoprotein E3 and E4 in cultured human brain neurons and astrocytes | Q30650547 |
| | Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice | Q31735508 |
| | Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line | Q33848287 |
| | Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system | Q34559847 |
| | Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease | Q35084110 |
| | Expression of apolipoprotein E during nerve degeneration and regeneration | Q35591346 |
| | Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice | Q35809803 |
| | Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice | Q35829683 |
| | Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice | Q35978742 |
| | Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice | Q36363956 |
| | Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease | Q36784564 |
| | Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B,E and apo-E receptors | Q37005091 |
| | Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons | Q37117670 |
| | Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases. | Q38306892 |
| | Receptor interactions controlling lipoprotein metabolism | Q39497638 |
| | Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia | Q39498138 |
| | Functional domains of apolipoprotein E and apolipoprotein B. | Q39509565 |
| | Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease | Q40397850 |
| | Neuropathological changes in Alzheimer disease | Q40670506 |
| | Apolipoprotein E: structure-function relationships | Q40737965 |
| | Cellular and molecular biology of Alzheimer's disease and animal models | Q40759701 |
| | Molecular biology of Alzheimer's disease | Q40771501 |
| | Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease | Q40849918 |
| | A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. | Q40965861 |
| | The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization | Q41308477 |
| | Exploring the etiology of Alzheimer disease using molecular genetics | Q41366388 |
| | Expression of apolipoprotein E by cultured vascular smooth muscle cells is controlled by growth state | Q41561900 |
| | Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease | Q41734485 |
| | Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle | Q41751580 |
| | Senile dementia of the Alzheimer type | Q42447051 |
| | Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology | Q42655700 |
| | Apoprotein E-rich high density lipoproteins inhibit ovarian androgen synthesis | Q43513413 |
| | Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells | Q43759044 |
| | Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation | Q44148114 |
| | APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress | Q44188924 |
| | Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. | Q44189963 |
| | Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease | Q44591025 |
| | ApoE isoforms affect neuronal N-methyl-D-aspartate calcium responses and toxicity via receptor-mediated processes | Q44653988 |
| | Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro | Q45081026 |
| | Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices | Q45233550 |
| | Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains | Q46421943 |
| | Is Alzheimer's disease an apolipoprotein E amyloidosis? | Q46974350 |
| | Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls | Q48092219 |
| | Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. | Q48143728 |
| | Phosphorylation state of tau in the hippocampus of apolipoprotein E4 and E3 knock-in mice | Q48337243 |
| P433 | issue | 1 | |
| P921 | main subject | proteolysis | Q33123 |
| P304 | page(s) | 73-80 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Journal of Molecular Neuroscience | Q15708870 |
| P1476 | title | Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain | |
| P478 | volume | 24 | |